# Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC

> **NCT07050043** · PHASE3 · RECRUITING · sponsor: **Dr Arvindran A/L Alaga** · enrollment: 123 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Carcinoma)
- First Line Therapy
- Locally Advanced/Metastatic NSCLC

## Interventions

- **DRUG:** Nivolumab 40mg
- **DRUG:** Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel

## Key facts

- **NCT ID:** NCT07050043
- **Lead sponsor:** Dr Arvindran A/L Alaga
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 123 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07050043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07050043, "Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07050043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*